Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

MACE benefits with dapagliflozin improve with disease duration

Key clinical point: Dapagliflozin cuts risk for cardiovascular disease or hospitalization for heart failure, regardless of diabetes duration, whereas the treatment effect for major adverse cardiovascular events and renal events differed by diabetes duration subgroup.

Major finding: The MACE hazard ratio ranged from 1.08 (disease duration, fewer than 5 years) to 0.67 (longer than 20 years).

Study details: Post hoc analysis of 17,160 patients in the DECLARE-TIMI 58 trial.

Disclosures: All but two of the authors reported relationships with Astra Zeneca, which funded the study, and other drug companies.

Citation:

Bajaj HS et al. Diabetes Obes Metab. 2020 Feb 23. doi: 10.1111/dom.14011.